middle.news
EMVision Advances emu™ Scanner Trials with $15.78M Cash Backing
7:03pm on Monday 2nd of June, 2025 AEST
•
Medical Devices
Read Story
EMVision Advances emu™ Scanner Trials with $15.78M Cash Backing
7:03pm on Monday 2nd of June, 2025 AEST
Key Points
Pre-validation EMView trial shows 92% sensitivity for haemorrhages
Validation trial for emu™ Bedside Scanner to start soon pending approvals
First Responder ultra-light brain scanner enters feasibility studies
Proforma cash reserves stand at $15.78 million including R&D tax rebate
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Emvision Medical Devices (ASX:EMV)
OPEN ARTICLE